An analyst runs an intact mass on a 30-residue synthetic peptide containing two methionines. The main species matches the expected mass, but a smaller signal sits 16 daltons higher. That shift is consistent with one added oxygen atom, and methionine oxidation is the obvious suspect. The intact spectrum cannot say which methionine is affected, or rule out oxidation somewhere else. To answer that, the analyst needs to break the molecule into pieces whose masses can be tied to positions in the sequence. That is peptide mapping.
Intact mass measures the whole molecule. A map tests the sequence region by region, which is why it is the routine technique that places a modification rather than merely detecting one.
How a map is built
The workflow has four steps, and each has a clear purpose:
- Digest. A protease with known cleavage rules cuts the peptide at predictable residues.
- Separate. Reverse-phase chromatography resolves the resulting fragments.
- Measure. A mass spectrometer records the mass of each eluting fragment.
- Compare. The observed masses are matched against a list calculated in advance from the expected sequence and the enzyme’s rules.
The comparison is the experiment. When every predicted fragment is found at its predicted mass, each covered stretch of the chain is consistent with the expected sequence. When a fragment appears at an unexpected mass, the discrepancy is confined to the residues inside that fragment. In the opening example, if the fragment containing the first methionine appears at +16 and the fragment containing the second is unchanged, the oxidation has been located.
Choosing the enzyme
A map is only readable because the cuts are specific. Random cleavage would produce a mixture nobody could interpret. The common choices differ in where they cut:
| Protease | Cleavage rule | Practical note |
|---|---|---|
| Trypsin | After lysine or arginine, not when the next residue is proline | The usual first choice; fragments tend to be a workable length |
| Chymotrypsin | After bulky hydrophobic residues such as phenylalanine, tryptophan and tyrosine | Useful where a sequence has few basic residues |
| Glu-C | After glutamate, and after aspartate under some buffer conditions | Buffer choice changes the fragment list |
| Asp-N | Before aspartate | Draws boundaries on the other side of acidic residues |
Because each enzyme puts boundaries in different places, a region that one digest leaves unreadable can often be covered by a second digest with a different enzyme. For a sequence rich in lysine and arginine, trypsin may produce fragments too short to use, and a less frequent cutter becomes the better option.
Coverage: the number that qualifies the result
Sequence coverage is the percentage of residues that appear in identified fragments. It is rarely 100 percent, and the reasons are built into the method. Very small fragments, such as a single residue between two cleavage sites, may not retain on the column or may be hard to detect. Very large, hydrophobic fragments may elute poorly or not at all. Some fragments ionize weakly. A long stretch with no cleavage sites produces one oversized piece that behaves badly at every stage.
Coverage therefore belongs in the result, not in a footnote. A report that states 94 percent coverage and names the uncovered residues is informative. A report that states no coverage figure leaves the reader unable to tell what was never examined.
Missed cleavages are expected
No protease cuts every available site on every molecule. A site next to a proline, beside a modified residue or inside a region that resists the enzyme may be skipped, producing a fragment that spans two predicted pieces. This is normal. Good interpretation uses a prediction list that includes plausible missed-cleavage products, so an unexpectedly long fragment is first checked against that list before anyone concludes it is new.
What the digestion can create
A map can report artifacts that the procedure itself introduced. Four are well known:
- Deamidation. Tryptic digests often run for hours at 37 °C near pH 8, conditions that promote deamidation. A deamidated fragment may reflect the digestion rather than the starting material.
- Disulfide scrambling. The same conditions can rearrange disulfide bonds, which is why connectivity work favors lower pH and faster enzymes where possible.
- Autolysis. The protease digests itself. Its fragments have known masses and are excluded during interpretation.
- Methionine oxidation. Methionine oxidizes easily during handling, so oxidation seen in a map does not by itself prove it was present beforehand.
The standard controls are a blank digest, containing the enzyme but no sample, and a reference material carried through the identical procedure. If the reference shows the same level of oxidation or deamidation as the test sample, the artifact explanation becomes hard to dismiss. For the opening example, that comparison decides whether the +16 signal belongs to the material or to the workflow.
Beyond locating an oxygen
The same logic places other changes: deamidation, a protecting group left over from synthesis, a substituted residue. The synthesis-related possibilities are outlined in peptide synthesis impurities. For disulfide connectivity, the peptide is digested without reducing the bonds, so fragments that remain linked reveal which cysteines are paired. Adding tandem mass spectrometry, which breaks each fragment again inside the instrument, can narrow a modification to a single residue.
Why most certificates do not include one
Mapping needs a digestion, a dedicated chromatographic run and expert interpretation. For a short peptide of a dozen or so residues, an accurate intact mass already constrains the composition tightly, and a map adds little. As chains get longer, intact mass becomes less decisive: a long molecule with one substituted residue can fall close enough to the expected mass that routine accuracy cannot separate them. That is where mapping earns its cost. Most routine release testing for short research peptides relies on purity by reverse-phase HPLC and identity by mass spectrometry. Every product page in the Battle Born catalog carries an independent reverse-phase HPLC result.
What a map does not establish
A map shows that observed fragments are consistent with the expected sequence within the covered region. It says nothing about the uncovered region. It does not address stereochemistry, because a D-residue produces a fragment of exactly the same mass as its L form. It does not measure purity, since the experiment characterizes a digest rather than separating the intact product from its impurities. Paired with intact mass and a purity trace, it answers the question those two cannot: whether the molecule is assembled in the right order.
Questions
What does sequence coverage mean?
The share of residues found in identified fragments. It should be reported alongside the result, with the uncovered region named.
Why use more than one enzyme?
Different enzymes cut in different places, so a region missed by one digest can often be read in another.
Can a map create modifications that were not there?
Yes. Digestion conditions can drive deamidation, disulfide scrambling and methionine oxidation. Blank digests and a reference carried through the same steps help separate artifacts from real features.
Does mapping confirm purity?
No. It tests sequence consistency. Purity is a chromatographic measurement on the intact material.
Research use only. All products supplied by Battle Born Peptides are laboratory reference materials for in-vitro research and analytical use by qualified professionals. They are not drugs, foods, dietary supplements, cosmetics or medical devices; they are not approved by the FDA or any other regulator for use in humans or animals; and they are not intended to diagnose, treat, cure, mitigate or prevent any disease, or to affect the structure or any function of the body of humans or animals. Nothing in this article is preparation, handling or dosing guidance. See our full research-use terms.